Explore what CDx Digital Education has to offer

Explore Training

Atlas of Stains

Explore a repository of real tissue samples stained with PD-L1 IHC 22C3 pharmDx, spanning the full range of PD-L1 expression across several indications.

PD-L1 IHC 28-8 pharmDx

Enhanced NSCLC, non-squamous NSCLC, SCCHN, and UC training programs with virtual microscope for increased confidence in scoring PD-L1 stained slides.

PD-L1 is a proven biomarker for patient response to KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC) (PD-L1 IHC 22C3 pharmDx [Instructions for Use], 2020). Review how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).

 


PD-L1 is a proven biomarker for patient response to KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC) (PD-L1 IHC 22C3 pharmDx [Instructions for Use], 2020). Review how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).

Lorem ipsum dolor sit amet consectetur. Enim dolor risus mattis proin. Sed arcu turpis nec lectus. Sit lorem ac lacinia nunc neque pretium id non. Elementum habitant enim duis morbi id id. Tincidunt ultrices eget vel aliquam interdum arcu id. Augue urna massa nec in nibh penatibus nulla. Iaculis tortor tellus consequat tincidunt enim.

Venenatis risus sed enim morbi quis. Sapien auctor pellentesque nisl aliquam vitae suscipit dignissim metus quam. Est quisque aliquam nullam non lobortis at egestas eu consectetur. Vitae ornare nunc sit aliquam. Tortor ornare nunc hendrerit diam ac quam sem et interdum. Nec ultricies at amet pulvinar tincidunt..The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:

  • abc
  • d
  • dld
  • dld
  • dld
  • dld

sdfsdfsfsfsf

sfsf

sfs

fsf

sfs

fs